Literature DB >> 15747334

Low risk episodes of fever and neutropenia in pediatric oncology: Is outpatient oral antibiotic therapy the new gold standard of care?

Roland A Ammann1, Arne Simon, Eveline S J M de Bont.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15747334     DOI: 10.1002/pbc.20287

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


× No keyword cloud information.
  6 in total

Review 1.  Outpatient and oral antibiotic management of low-risk febrile neutropenia are effective in children--a systematic review of prospective trials.

Authors:  A Manji; J Beyene; L L Dupuis; R Phillips; T Lehrnbecher; L Sung
Journal:  Support Care Cancer       Date:  2012-03-09       Impact factor: 3.603

2.  H-ficolin serum concentration and susceptibility to fever and neutropenia in paediatric cancer patients.

Authors:  L J Schlapbach; C Aebi; A G Hansen; A Hirt; J C Jensenius; R A Ammann
Journal:  Clin Exp Immunol       Date:  2009-07       Impact factor: 4.330

3.  Outpatient management of febrile neutropenia in children with cancer.

Authors:  Ottavio Ziino; Fabio Tucci; Mario Renato Rossi
Journal:  Pediatr Rep       Date:  2011-02-24

Review 4.  Systematic review and meta-analysis of the value of initial biomarkers in predicting adverse outcome in febrile neutropenic episodes in children and young people with cancer.

Authors:  Robert S Phillips; Ros Wade; Thomas Lehrnbecher; Lesley A Stewart; Alex J Sutton
Journal:  BMC Med       Date:  2012-01-18       Impact factor: 8.775

Review 5.  Predicting infectious complications in neutropenic children and young people with cancer (IPD protocol).

Authors:  Robert S Phillips; Alex J Sutton; Richard D Riley; Julia C Chisholm; Susan V Picton; Lesley A Stewart
Journal:  Syst Rev       Date:  2012-02-09

6.  Pro-inflammatory cytokine ratios determine the clinical course of febrile neutropenia in children receiving chemotherapy.

Authors:  Mira Siegmund; Julia Pagel; Tasja Scholz; Jan Rupp; Christoph Härtel; Melchior Lauten
Journal:  Mol Cell Pediatr       Date:  2020-06-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.